Immunotherapy drug improves outcomes for some children with relapsed leukemia

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

Tags:

2019
news
leukemia
ALL
B-ALL

To wipe childhood cancer off the map, scientists must chart its genomic landscape

Childhood Liver Cancer "Signatures" May Help Predict Response to Chemo

New chemical technology leads to better targeted therapeutics against high-risk leukemia in the lab

Hopes of a new curative treatment for children with neuroblastoma

Scientists are a step closer to finding a low toxicity treatment for childhood leukaemia

Researchers identify an Achilles’ heel in neuroblastoma

To save children with cancer, doctors turn to new weapons

Childhood Cancer Survivors Are at an Increased Risk for Hospitalization Years After Treatment Ends

Novel targeted therapy could be effective treatment option for deadly childhood cancer

Gene That Causes Deadliest Brain Tumor Also Causes Childhood Cancer

Recent Posts

Immunotherapy drug improves outcomes for some children with relapsed leukemia

Archive

Search By Tags